Home>Topics>Stocks>Momenta Pharmaceuticals

Momenta Pharmaceuticals MNTA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Momenta Pharmaceuticals Heading For A Repeat

      Headlines

      Tue, 5 Aug 2014

      Cory Renauer: While most promising young biotechs devote all resources to development of new drugs, Momenta Pharmaceuticals (NASDAQ: MNTA ) is adopting a fairly unusual strategy of aiming for the middle. Its plan for developing biosimilars

    2. 2nd Half Of 2014 Biotechnology Catalysts-Part 3

      Headlines

      Mon, 4 Aug 2014

      By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little

    3. Momenta's ( MNTA ) CEO Craig Wheeler on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 31 Jul 2014

      Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ) Q2 2014 Results Earnings Conference Call July 31 ..... gentlemen, and thank you for standing by. Welcome to the Momenta Pharmaceuticals ’ Second Quarter 2014 Earnings Call. At this time

    4. More on Momenta Q2 results

      Headlines

      Thu, 31 Jul 2014

      Momenta Pharmaceuticals ( MNTA -3.5% ) Q2 results : Collaboration revenue: $11.0M (+151.1%); Operating Expenses: $37.3M (+11.3%); Operating

    5. Momenta Pharmaceuticals misses by $0.07, misses on revenue

      Headlines

      Thu, 31 Jul 2014

      Momenta Pharmaceuticals (NASDAQ: MNTA ): Q2 EPS of -$0.51 misses by $0.07 . Revenue of $10.95M (+151.1% Y/Y) misses by $0.27M . Press Release Post your comment!

    6. Notable earnings before Thursday’s open

      Headlines

      Wed, 30 Jul 2014

      GTLS , H , HGG , HL , HP , HST , IDA , IMN , INCY , IRDM , IRM , ITT , IVZ , K , KMT , LKQ , LLL , LM , MA , MCK , MD , MDP , MNTA , MOD , MOS , MPC , MPLX , MSCI , MTOR , MWIV , NGD , NI , NJR , NWL , OAK , OCN , ODFL , OXY , PCG , PCRX , PES , PNR , PNW

    7. New Morningstar Analyst Report for Momenta Pharmaceuticals Inc

      Stock Reports

      Mon, 9 Jun 2014

      Increasing pharmaceutical complexity shines light on Momenta's capabilities.

    8. U.S. Supreme Court Decision is Minor Plus for Teva

      Commentary

      Mon, 31 Mar 2014

      Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic

    9. Momenta Awaits Potential Generic Copaxone Decision

      Commentary

      Wed, 6 Nov 2013

      We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million

    10. Patent Litigation Creates Earlier-Than-Expected Generic Copaxone Launch Opportunity

      Commentary

      Fri, 2 Aug 2013

      We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U

    « Prev1234Next »
    Content Partners